Company overview
Genomic Testing Cooperative (GTC) provides comprehensive DNA and RNA next-generation sequencing (NGS) for solid tumors and hematologic malignancies, including liquid biopsy options. Their cooperative model partners with labs, hospitals, and oncology practices to share resources, reduce costs, and enable faster turnaround times of 5-10 days using AI-driven informatics. Tests are Medicare-covered, with reporting including therapy recommendations and clinical trial matches.
Genomic Testing Cooperative is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include genomic testing, ngs oncology, dna rna sequencing, liquid biopsy, cancer profiling.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://genomictestingcooperative.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- genomic testing, ngs oncology, dna rna sequencing, liquid biopsy, cancer profiling
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What testing capabilities does GTC offer?
- GTC offers comprehensive genomic profiling with DNA and RNA NGS panels for solid tumors, hematologic neoplasms, liquid biopsies, and CSF, including fusion detection, alternative splicing, gene expression, and AI-enhanced reporting with therapy and trial recommendations.
- What is GTC's cooperative model and service options?
- GTC's co-op model allows partners to select services like in-house genomics labs managed by GTC, cooperative associate, or reference lab, sharing resources, expertise, and big data for innovation while localizing cancer care.
- What are GTC's turnaround times and coverage?
- Turnaround time is 5-10 days. All tests are well-validated and covered by Medicare, with direct insurance billing handled by GTC including appeals.
Related editorial coverage
- FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
- Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
